These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12412487)

  • 1. Tailoring natural effector functions. Antibody engineering beyond humanization.
    Brekke OH; Thommesen JE
    Methods Mol Biol; 2003; 207():383-91. PubMed ID: 12412487
    [No Abstract]   [Full Text] [Related]  

  • 2. Isotype selection in antibody engineering.
    Salfeld JG
    Nat Biotechnol; 2007 Dec; 25(12):1369-72. PubMed ID: 18066027
    [No Abstract]   [Full Text] [Related]  

  • 3. Design of humanized antibodies: from anti-Tac to Zenapax.
    Tsurushita N; Hinton PR; Kumar S
    Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of humanized IgGs in glycoengineered Pichia pastoris.
    Li H; Sethuraman N; Stadheim TA; Zha D; Prinz B; Ballew N; Bobrowicz P; Choi BK; Cook WJ; Cukan M; Houston-Cummings NR; Davidson R; Gong B; Hamilton SR; Hoopes JP; Jiang Y; Kim N; Mansfield R; Nett JH; Rios S; Strawbridge R; Wildt S; Gerngross TU
    Nat Biotechnol; 2006 Feb; 24(2):210-5. PubMed ID: 16429149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies in the breakdown lane.
    Blumberg RS; Lencer WI
    Nat Biotechnol; 2005 Oct; 23(10):1232-4. PubMed ID: 16211062
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification and verification of hybridoma-derived monoclonal antibody variable region sequences using recombinant DNA technology and mass spectrometry.
    Babrak L; McGarvey JA; Stanker LH; Hnasko R
    Mol Immunol; 2017 Oct; 90():287-294. PubMed ID: 28865256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular engineering of a therapeutic antibody for Blo t 5-induced allergic asthma.
    Chan JHS; Chua YL; Peh HY; Jovanovic V; Gascoigne NRJ; Wong WSF; Chew FT; Hanson BJ; Kemeny DM; MacAry PA
    J Allergy Clin Immunol; 2017 May; 139(5):1705-1708.e6. PubMed ID: 27923562
    [No Abstract]   [Full Text] [Related]  

  • 8. Tunable antibodies.
    Weiner LM; Carter P
    Nat Biotechnol; 2005 May; 23(5):556-7. PubMed ID: 15877072
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibody humanization: a case of the 'Emperor's new clothes'?
    Clark M
    Immunol Today; 2000 Aug; 21(8):397-402. PubMed ID: 10916143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimerization of a monoclonal antibody for treating Hodgkin's lymphoma.
    Krauss J; Förster HH; Uchanska-Ziegler B; Ziegler A
    Methods Mol Biol; 2003; 207():63-79. PubMed ID: 12412468
    [No Abstract]   [Full Text] [Related]  

  • 11. Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies.
    Ouisse LH; Gautreau-Rolland L; Devilder MC; Osborn M; Moyon M; Visentin J; Halary F; Bruggemann M; Buelow R; Anegon I; Saulquin X
    BMC Biotechnol; 2017 Jan; 17(1):3. PubMed ID: 28081707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for generating multivalent and bispecific antibody fragments.
    Tomlinson I; Holliger P
    Methods Enzymol; 2000; 326():461-79. PubMed ID: 11036658
    [No Abstract]   [Full Text] [Related]  

  • 13. Simultaneous humanization and affinity optimization of monoclonal antibodies.
    Wu H
    Methods Mol Biol; 2003; 207():197-212. PubMed ID: 12412476
    [No Abstract]   [Full Text] [Related]  

  • 14. Generation of humanized monoclonal antibodies by 'best fit' framework selection and recombinant polymerase chain reaction.
    Lewis AP; Crowe JS
    Year Immunol; 1993; 7():110-8. PubMed ID: 8372500
    [No Abstract]   [Full Text] [Related]  

  • 15. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
    McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
    Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic antibodies and antibody fusion proteins.
    Rohrbach P; Broders O; Toleikis L; Dübel S
    Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
    [No Abstract]   [Full Text] [Related]  

  • 18. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering therapeutic monoclonal antibodies.
    Liu XY; Pop LM; Vitetta ES
    Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanization and characterization of the anti-HLA-DR antibody 1D10.
    Kostelny SA; Link BK; Tso JY; Vasquez M; Jorgensen BH; Wang H; Hall WC; Weiner GJ
    Int J Cancer; 2001 Aug; 93(4):556-65. PubMed ID: 11477560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.